secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066426
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)
-------------------------------------------------------------

- 1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).
- Royalty revenue $30M (+32%) from increased Tyvaso DPI demand; collaborations & services $29.4M (+18%) from United Therapeutics.
- Afrezza NRx grew 20% YoY; sBLA for pediatric approval expected mid-2025.
- MNKD-101 Phase 3 ICON-1: 55 patients randomized, 85% sites activated; target 100 patients by YE 2025.
- Cash & investments $198M; MNKD-201 (nintedanib DPI) expected to advance to next phase in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/0000950170-25-066426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer